Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZRXTL)

Drug Name

E7820 Drug Info

Synonyms

E7820; 289483-69-8; E-7820; E 7820; UNII-TVH5K7949N; TVH5K7949N; 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide; NSC-719239; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide; Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)-; LWGUASZLXHYWIV-UHFFFAOYSA-N; AC1L52N5; ZINC8704; SCHEMBL1581157; DTXSID20183142; BCP25835; EX-A1818; 3-Cyano-N-(3-cyano-4-methyl-1H-indole-7-yl)benzensulfonamide; NSC719239; AKOS032944953; CS-6075

Indication

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]

Cross-matching ID

PubChem CID: 196970
CAS Number: CAS 289483-69-8
TTD Drug ID: DMZRXTL

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Integrin alpha-2 (ITGA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
3-(3-(carbamoyl)benzamido)propanoic acid	DM31JAZ	Discovery agent	N.A.	Investigative	[3]
3-(3-(benzamido)-5-nitrobenzamido)propanoic acid	DMY4VX2	Discovery agent	N.A.	Investigative	[3]
3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid	DM2K51S	Discovery agent	N.A.	Investigative	[3]
MAGGIEMYCIN	DMSQL19	Discovery agent	N.A.	Investigative	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Integrin alpha-2 (ITGA2)	TTSJ542	ITA2_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00309179) A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors. U.S. National Institutes of Health.
2	Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin Cancer Res. 2011 Jan 1;17(1):193-200.
3	Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5294-7.
4	Small molecule designed to target metal binding site in the alpha2I domain inhibits integrin function. J Med Chem. 2007 May 31;50(11):2742-6.